ReviewMolecular medicine reports2025
Hyperbaric oxygen therapy for sudden sensorineural hearing loss (Review).
Review in Molecular medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pathophysiologic phenotyping of idiopathic sudden sensorineural hearing loss: toward precision management.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Review
- Semicircular canal dysfunction in profound sudden sensorineural hearing loss and its prognostic value: implications for the proper indication of hyperbaric oxygen therapy.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sudden sensorineural hearing loss (SSNHL) is an acute hearing disorder that develops rapidly and is an otolaryngology emergency. Hyperbaric oxygen therapy (HBOT), a non‑pharmacological treatment, has gained increasing attention for SSNHL management. HBOT exerts therapeutic effects by increasing inner ear oxygen partial pressure, improving the microcirculation and reducing inflammation, as its main mechanisms. When combined with glucocorticoids, HBOT can significantly improve treatment outcomes, particularly when initiated as an early intervention. However, its optimal clinical application has not yet been determined, mainly due to the lack of standardized treatment parameters, such as pressure settings, the duration of treatment and the therapeutic time window. In addition, clinical studies have yielded inconsistent results. The purpose of the present review is to explore the biological mechanisms, clinical efficacy and existing controversies of HBOT in the treatment of SSNHL, review and summarize the latest research progress, and discuss potential directions for future development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.